title: Critical assessment of pharmaceutical processes--A rationale for changing the synthetic route.
authors.affiliation: AstraZeneca, Process R&D, Avlon/Charnwood, Avlon Works, Severn Road, Hallen, Bristol BS10 7ZE, UK. Mike.Butters@astrazeneca.com
authors.forename: Mike
authors.initials: M
authors.lastname: Butters
authors.forename: David
authors.initials: D
authors.lastname: Catterick
authors.forename: Andrew
authors.initials: A
authors.lastname: Craig
authors.forename: Alan
authors.initials: A
authors.lastname: Curzons
authors.forename: David
authors.initials: D
authors.lastname: Dale
authors.forename: Adam
authors.initials: A
authors.lastname: Gillmore
authors.forename: Stuart P
authors.initials: SP
authors.lastname: Green
authors.forename: Ivan
authors.initials: I
authors.lastname: Marziano
authors.forename: Jon-Paul
authors.initials: JP
authors.lastname: Sherlock
authors.forename: Wesley
authors.initials: W
authors.lastname: White
mesh_terms: D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards; D064420:Drug-Related Side Effects and Adverse Reactions; D007880:Legislation, Drug; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis* / Q000737:chemistry; D012449:Safety
chemical_list: D004364:Pharmaceutical Preparations